All In Biotech

NDA 022548 · Abbvie

Zymaxid

Gatifloxacin · Ophthalmic

Last checked: Nov 20, 2026Latest source record: Sep 8, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

May 18, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

33

7 Phase 3, 1 recruiting

FAERS reports

1,785

1,437 serious, 106 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 8, 2016.

ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections . ZYMAXID ® is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group , Streptococcus oralis, Streptococcus pneumoniae ( 1 )

Mechanism: Gatifloxacin is a quinolone antimicrobial [ see Microbiology ( 12.4 ) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZYMAXID · GATIFLOXACIN 0.5% · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Gatifloxacin" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypoglycaemia151
  • hyperglycaemia96
  • anaphylactic reaction85
  • drug intolerance83
  • drug ineffective79
  • diarrhoea71
  • eye pain68
  • dizziness58
  • off label use56
  • dyspnoea55
  • rash55
  • nausea50

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004299
2005309
2006119
200742
200847
200937
201040
201155
201269
201341
201448
201549
201656
201762
201877
2019100
202062
202151
202253
202340
202439
202541
202649

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 163 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.